Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.

A recent study analysed the relationship between neutralising antibody response and protection from SARS-CoV-2 infection across eight vaccines platforms. The efficacy results from a phase 2b/3 trial of a ninth vaccine candidate, CVnCoV (CUREVAC), was announced on 16 June 2021. The low efficacy of this new mRNA vaccine, which showed only 47% protection from symptomatic SARS-CoV-2 infection, was surprising, given the high efficacy of two previous mRNA-based vaccines. A number of factors have been suggested to play a role in the low efficacy in the CVnCoV study, particularly around the dose and immunogenicity of the vaccine (which uses a slightly different mRNA construct) and the potential role of infection with SARS-CoV-2 variants (which were the dominant strains observed in the CVnCoV trial).